|
1
|
Ringelhan M, Pfister D, O'Connor T,
Pikarsky E and Heikenwalder M: The immunology of hepatocellular
carcinoma. Nat Immunol. 19:222–232. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu J, Yang HI, Lee MH, Lu SN, Jen CL,
Batrla-Utermann R, Wang LY, You SL, Hsiao CK, Chen PJ, et al:
Spontaneous seroclearance of hepatitis B seromarkers and subsequent
risk of hepatocellular carcinoma. Gut. 63:1648–1657. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Levrero M and Zucman-Rossi J: Mechanisms
of HBV-induced hepatocellular carcinoma. J Hepatol. 64 (1
Suppl):S84–S101. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shtivelman E, Henglein B, Groitl P, Lipp M
and Bishop JM: Identification of a human transcription unit
affected by the variant chromosomal translocations 2;8 and 8;22 of
Burkitt lymphoma. Proc Natl Acad Sci USA. 86:3257–3260. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Huppi K, Siwarski D, Skurla R, Klinman D
and Mushinski JF: Pvt-1 transcripts are found in normal tissues and
are altered by reciprocal(6;15) translocations in mouse
plasmacytomas. Proc Natl Acad Sci USA. 87:6964–698. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Barsotti AM, Beckerman R, Laptenko O,
Huppi K, Caplen NJ and Prives C: p53-Dependent induction of PVT1
and miR-1204. J Biol Chem. 287:2509–2519. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Guan Y, Kuo WL, Stilwell JL, Takano H,
Lapuk AV, Fridlyand J, Mao JH, Yu M, Miller MA, Santos JL, et al:
Amplification of PVT1 contributes to the pathophysiology of ovarian
and breast cancer. Clin Cancer Res. 13:5745–5755. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Takahashi Y, Sawada G, Kurashige J, Uchi
R, Matsumura T, Ueo H, Takano Y, Eguchi H, Sudo T, Sugimachi K, et
al: Amplification of PVT-1 is involved in poor prognosis via
apoptosis inhibition in colorectal cancers. Br J Cancer.
110:164–171. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ding J, Li D, Gong M, Wang J, Huang X, Wu
T and Wang C: Expression and clinical significance of the long
non-coding RNA PVT1 in human gastric cancer. OncoTargets Ther.
7:1625–1630. 2014. View Article : Google Scholar
|
|
10
|
Yang YR, Zang SZ, Zhong CL, Li YX, Zhao SS
and Feng XJ: Increased expression of the lncRNA PVT1 promotes
tumorigenesis in non-small cell lung cancer. Int J Clin Exp Pathol.
7:6929–6935. 2014.PubMed/NCBI
|
|
11
|
Xu Y, Luo X, He W, Chen G, Li Y, Li W,
Wang X, Lai Y and Ye Y: Long non-coding RNA PVT1/miR-150/HIG2 axis
regulates the proliferation, invasion and the balance of iron
metabolism of hepatocellular carcinoma. Cell Physiol Biochem.
49:1403–1419. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Guo J, Hao C, Wang C and Li L: Long
noncoding RNA PVT1 modulates hepatocellular carcinoma cell
proliferation and apoptosis by recruiting EZH2. Cancer Cell Int.
18:982018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Derderian C, Orunmuyi AT, Olapade-Olaopa
EO and Ogunwobi OO: PVT1 signaling is a mediator of cancer
progression. Front Oncol. 9:5022019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cui M, You L, Ren X, Zhao W, Liao Q and
Zhao Y: Long non-coding RNA PVT1 and cancer. Biochem Biophys Res
Commun. 471:10–4. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen L, Sun L, Dong L, Cui P, Xia Z, Li C
and Zhu Y: The role of long noncoding RNA-LET in cell proliferation
and invasion of nasopharyngeal carcinoma and its mechanism.
OncoTargets Ther. 10:2769–2778. 2017. View Article : Google Scholar
|
|
16
|
Davidovich C and Cech TR: The recruitment
of chromatin modifiers by long noncoding RNAs: Lessons from PRC2.
RNA. 21:2007–2022. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Khalil AM, Guttman M, Huarte M, Garber M,
Raj A, Rivea Morales D, Thomas K, Presser A, Bernstein BE, van
Oudenaarden A, et al: Many human large intergenic noncoding RNAs
associate with chromatin-modifying complexes and affect gene
expression. Proc Natl Acad Sci USA. 106:11667–116672. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
He A, Shen X, Ma Q, Cao J, von Gise A,
Zhou P, Wang G, Marquez VE, Orkin SH and Pu WT: PRC2 directly
methylates GATA4 and represses its transcriptional activity. Genes
Dev. 26:37–42. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen Y, Lin MC, Wang H, Chan CY, Jiang L,
Ngai SM, Yu J, He ML, Shaw PC, Yew DT, et al: Proteomic analysis of
EZH2 downstream target proteins in hepatocellular carcinoma.
Proteomics. 7:3097–3104. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Villanueva A: Hepatocellular Carcinoma. N
Engl J Med. 380:1450–1462. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pfeiffer E, Kegel V, Zeilinger K,
Hengstler JG, Nüssler AK, Seehofer D and Damm G: Featured article:
Isolation, characterization, and cultivation of human hepatocytes
and non-parenchymal liver cells. Exp Biol Med (Maywood).
240:645–656. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Colombo T, Farina L, Macino G and Paci P:
PVT1: A rising star among oncogenic long noncoding RNAs. Biomed Res
Int. 2015:3042082015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xu MD, Wang Y, Weng W, Wei P, Qi P, Zhang
Q, Tan C, Ni SJ, Dong L, Yang Y, et al: A positive feedback loop of
lncRNA-PVT1 and FOXM1 facilitates gastric cancer growth and
invasion. Clin Cancer Res. 23:2071–2080. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang XW, Bu P, Liu L, Zhang XZ and Li J:
Overexpression of long non-coding RNA PVT1 in gastric cancer cells
promotes the development of multidrug resistance. Biochem Biophys
Res Commun. 462:227–232. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ezhkova E, Pasolli HA, Parker JS, Stokes
N, Su IH, Hannon G, Tarakhovsky A and Fuchs E: Ezh2 orchestrates
gene expression for the stepwise differentiation of tissue-specific
stem cells. Cell. 136:1122–1135. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gao SB, Zheng QF, Xu B, Pan CB, Li KL,
Zhao Y, Zheng QL, Lin X, Xue LX and Jin GH: EZH2 represses target
genes through H3K27-dependent and H3K27-independent mechanisms in
hepatocellular carcinoma. Mol Cancer Res. 12:1388–1397. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kong R, Zhang EB, Yin DD, You LH, Xu TP,
Chen WM, Xia R, Wan L, Sun M, Wang ZX, et al: Long noncoding RNA
PVT1 indicates a poor prognosis of gastric cancer and promotes cell
proliferation through epigenetically regulating p15 and p16. Mol
Cancer. 14:822015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang S, Zhang G and Liu J: Long noncoding
RNA PVT1 promotes cervical cancer progression through
epigenetically silencing miR-200b. APMIS. 124:649–658. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wan L, Sun M, Liu GJ, Wei CC, Zhang EB,
Kong R, Xu TP, Huang MD and Wang ZX: Long noncoding RNA PVT1
promotes non-small cell lung cancer cell proliferation through
epigenetically regulating LATS2 expression. Mol Cancer Ther.
15:1082–1094. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tseng YY, Moriarity BS, Gong W, Akiyama R,
Tiwari A, Kawakami H, Ronning P, Reuland B, Guenther K, Beadnell
TC, et al: PVT1 dependence in cancer with MYC copy-number increase.
Nature. 512:82–86. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Clark DN and Hu J: Hepatitis B virus
reverse transcriptase-target of current antiviral therapy and
future drug development. Antiviral Res. 123:132–137. 2015.
View Article : Google Scholar : PubMed/NCBI
|
